Min Luo

Dr. Min Luo

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2018 in Science
Verified
Journal Article
Closed access
PDF file
ASAnurag P. Srivastava
Anurag P. Srivastava
MLMin Luo
Min Luo
WZWenchang Zhou
Wenchang Zhou
JSJindrich Symersky
Jindrich Symersky
DBDongyang Bai
Dongyang Bai
DMDavid M. Mueller
David M. Mueller
Protons find a path: Adenosine triphosphate (ATP) synthases are dynamos that interconvert rotational and chemical energy. Capturing the complete structure of these multisubunit membrane-bound complexes has been hindered by their inherent ability to adopt multiple conformations. Srivastava et al. used protein engineering to freeze mitochondrial ATP synthase from yeast in a single conformation and obtained a structure with the inhibitor oligomycin, which binds to the rotating c-ring within the membrane. Hahn et al. show that chloroplast ATP synthase contains a built-in inhibitor triggered by oxidizing conditions in the dark chloroplast. The mechanisms by which these machines are powered are remarkably similar: Protons are shuttled through a channel to the membrane-embedded c-ring, where they drive nearly a full rotation of the rotor before exiting through another channel on the opposite side of the membrane (see the Perspective by Kane). Science , this issue p. eaas9699 , p. eaat4318 ; see also p. 600

6 July 2018 in Science
Verified
Journal Article
Closed access
PDF file
YXYibei Xiao
Yibei Xiao
MLMin Luo
Min Luo
ADAdam E. Dolan
Adam E. Dolan
MLMaofu Liao
Maofu Liao
AKAilong Ke
Ailong Ke
Target degradation of Type I CRISPR: The CRISPR adaptive immune systems defend bacteria against invaders. Type I CRISPR-Cas systems, the most prevalent type, use a Cascade complex to search the target DNA that is then degraded by Cas3 protein. Xiao et al. report cryo–electron microscopy structures of the Type I-E Cascade/Cas3 complex in the pre– and post–DNA-nicking states. These structures reveal how Cas3 captures Cascade only in its correct conformation to reduce off-targeting and how Cas3 switches from the initial DNA-nicking mode to the processive DNA degradation mode. Science , this issue p. eaat0839

25 April 2025 in Science
Verified
Journal Article
Closed access
ZZZhifeng Zeng
Zhifeng Zeng
ZHZeyu Hu
Zeyu Hu
RZRuiliang Zhao
Ruiliang Zhao
JRJikai Rao
Jikai Rao
MMMario Rodríguez Mestre
Mario Rodríguez Mestre
WHWenyuan Han
Wenyuan Han
Signaling from pathogen sensing to effector activation is a fundamental principle of cellular immunity. Whereas cyclic (oligo)nucleotides have emerged as key signaling molecules, the existence of other messengers remains largely unexplored. In this study, we reveal a bacterial antiphage system that mediates immune signaling through nucleobase modification. Immunity is triggered by phage nucleotide kinases, which, combined with the system-encoded adenosine deaminase, produce deoxyinosine triphosphates (dITPs) as immune messengers. The dITP signal activates a downstream effector to mediate depletion of cellular nicotinamide adenine dinucleotide (oxidized form), resulting in population-level defense through the death of infected cells. To counteract immune signaling, phages deploy specialized enzymes that deplete cellular deoxyadenosine monophosphate, the precursor of dITP messengers. Our findings uncover a nucleobase modification–based antiphage signaling pathway, establishing noncanonical nucleotides as a new type of immune messengers in bacteria.

15 May 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
XXXin Xu
Xin Xu
JLJianwei Li
Jianwei Li
WCWan-Zhen Chua
Wan-Zhen Chua
MPMartin A. Pages
Martin A. Pages
JSJian Shi
Jian Shi
MLMin Luo
Min Luo
The peptidoglycan (PG) cell wall produced by the bacterial division machinery is initially shared between the daughters and must be split to promote cell separation and complete division. In gram-negative bacteria, enzymes that cleave PG called amidases play major roles in the separation process. To prevent spurious cell wall cleavage that can lead to cell lysis, amidases like AmiB are autoinhibited by a regulatory helix. Autoinhibition is relieved at the division site by the activator EnvC, which is in turn regulated by the ATP-binding cassette (ABC) transporter-like complex called FtsEX. EnvC is also known to be autoinhibited by a regulatory helix (RH), but how its activity is modulated by FtsEX and the mechanism by which it activates the amidases have remained unclear. Here, we investigated this regulation by determining the structure ofPseudomonas aeruginosaFtsEX alone with or without bound ATP, in complex with EnvC, and in a FtsEX–EnvC–AmiB supercomplex. In combination with biochemical studies, the structures reveal that ATP binding is likely to activate FtsEX-EnvC and promote its association with AmiB. Furthermore, the AmiB activation mechanism is shown to involve a RH rearrangement. In the activated state of the complex, the inhibitory helix of EnvC is released, freeing it to associate with the RH of AmiB, which liberates its active site for PG cleavage. These regulatory helices are found in many EnvC proteins and amidases throughout gram-negative bacteria, suggesting that the activation mechanism is broadly conserved and a potential target for lysis-inducing antibiotics that misregulate the complex.

17 February 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
WFWenjie of Biological Fan
Wenjie of Biological Fan
KSKai Shao
Kai Shao
MLMin Luo
Min Luo
ATP-binding cassette (ABC) transporters, acting as cellular “pumps,” facilitate solute translocation through membranes via ATP hydrolysis. Their overexpression is closely tied to multidrug resistance (MDR), a major obstacle in chemotherapy and neurological disorder treatment, hampering drug accumulation and delivery. Extensive research has delved into the intricate interplay between ABC transporter structure, function, and potential inhibition for MDR reversal. Cryo-electron microscopy has been instrumental in unveiling structural details of various MDR-causing ABC transporters, encompassing ABCB1, ABCC1, and ABCG2, as well as the recently revealed ABCC3 and ABCC4 structures. The newly obtained structural insight has deepened our understanding of substrate and drug binding, translocation mechanisms, and inhibitor interactions. Given the growing body of structural information available for human MDR transporters and their associated mechanisms, we believe it is timely to compile a comprehensive review of these transporters and compare their functional mechanisms in the context of multidrug resistance. Therefore, this review primarily focuses on the structural aspects of clinically significant human ABC transporters linked to MDR, with the aim of providing valuable insights to enhance the effectiveness of MDR reversal strategies in clinical therapies.

Verified
Journal Article
Open access
PDF file
STShi Ting Tia
Shi Ting Tia
MLMin Luo
Min Luo
WFWenjie of Biological Fan
Wenjie of Biological Fan
P-glycoprotein (P-gp/ABCB1), a key ATP-binding cassette (ABC) transporter, plays a central role in multidrug resistance (MDR), one of the leading causes of chemotherapy failure in cancer treatment. P-gp actively pumps chemotherapeutic agents out of cancer cells, reducing intracellular drug concentration and compromising therapeutic efficacy. Recent advancements in structural biology, particularly cryogenic electron microscopy (cryo-EM), have revealed detailed conformational states of P-gp, providing unprecedented insights into its transport mechanisms. In parallel, studies have identified various P-gp mutants in cancer patients, many of which are linked to altered drug efflux activity and resistance phenotypes. This review systematically examines recent structural studies of P-gp, correlates known patient-derived mutations to their functional consequences, and explores their impact on MDR. We propose plausible mechanisms by which these mutations affect P-gp’s activity based on structural evidence and discuss their implications for chemotherapy resistance. Additionally, we review current approaches for P-gp inhibition, a critical strategy to restore drug sensitivity in resistant cancers, and outline future research directions to combat P-gp-mediated MDR.